Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE)
- 6 December 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Infectious Disease Reports
- Vol. 18 (12), 48
- https://doi.org/10.1007/s11908-016-0548-3
Abstract
Carbapenems are the broadest spectrum antimicrobials utilized in the treatment of serious infections since the 1980s. Soon after their introduction, the discovery of carbapenem-resistant Enterobacteriaceae (CRE) was reported in the 1990s. Invasive CRE infections are associated with high mortality and limited treatment options making care for patients with these infections challenging for clinicians. Current practice has reverted back to the use of "older" antimicrobials, such as the polymyxins, tigecycline, and fosfomycin, to combat invasive CRE infections. However, recent approval of ceftazidime-avibactam has added another treatment option to the current antimicrobial armamentarium. Resistance among the "older" agents is still rare but has been reported. Currently, there are numerous agents that are under investigation as well as combination therapy that looks promising in the treatment of CRE infections.Keywords
This publication has 53 references indexed in Scilit:
- Molecular Dissection of an Outbreak of Carbapenem-Resistant Enterobacteriaceae Reveals Intergenus KPC Carbapenemase Transmission through a Promiscuous PlasmidmBio, 2011
- Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from UrineAntimicrobial Agents and Chemotherapy, 2011
- Carbapenems: Past, Present, and FutureAntimicrobial Agents and Chemotherapy, 2011
- Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2011
- Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infectionsDiagnostic Microbiology and Infectious Disease, 2011
- In Vitro Activity of Fosfomycin against bla(KPC)-Containing Klebsiella pneumoniae Isolates, Including Those Nonsusceptible to Tigecycline and/or ColistinAntimicrobial Agents and Chemotherapy, 2009
- ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae IsolatesAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC CarbapenemasesAntimicrobial Agents and Chemotherapy, 2009
- Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USAJournal of Antimicrobial Chemotherapy, 2009
- Presence of Plasmid-Mediated Quinolone Resistance in Klebsiella pneumoniae Isolates Possessing bla KPC in the United StatesAntimicrobial Agents and Chemotherapy, 2008